# US 2011/0086051 A1 · System and method for monitoring and optimizing immune status in transplant recipients

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2011/0086051 A1
- Document ID: US20110086051A1
- Status: Published application
- Kind: A1
- Application number: 12/900,450
- Filed: 2010-10-07
- Published: 2011-04-14
- Earliest claimed: 2009-10-08
- Assignees: Dartmouth-Hitchcock Clinic
- Inventors: Richard A. Zuckerman; Michael C. Chobanian
- Web page: https://patentgrep.com/patent/US20110086051A1

## CPC

- C12Q 1/6876: Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C12Q 1/6806: Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence)
- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 2600/112: Disease subtyping, staging or classification
- C12Q 2600/158: Expression markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention provides a system and method for an assay used in determining appropriate immunosuppressant levels relative to organ transplant in which PBMC is separated from whole blood by Ficoll®. An aliquot of PBMC is used for phenotyping of cells. CD4, CD8, memory and naïve subsets, B-cells regulatory T-cells and other cell markers (e.g. CD31) are examined. After an aliquot of PBMC is taken, CD4 cells are isolated. DNA is isolated from the cells. CD4 cells can be used for TREC at the defined time points. The TREC assay can be performed via a validated protocol. TREC levels are then measured using a quantitative RT-PCR for single jointed TREC. Alternatively, or additionally, TREC-correlated cell markers (e.g. CD31) can be analyzed. Approximately 100,000 cells, or 2 micrograms, of DNA are desired for TREC analysis. Normal control cells are run in parallel. A kit for performing the assay, including instructions and various components can be provided for practitioners.

## Claims

### Claim 1

A method for the detection and quantification of T-cell receptor excision circles in an organ transplant recipient comprising:
separating a peripheral blood mononuclear cell from whole blood;
examining at least one of CD4, CD8, memory and naïve subsets, B-cells, regulatory T-cells and other cell markers;
isolating DNA of CD4 cells;
performing a TREC analysis on the CD4 cells;
determining immune status of the organ transplant recipient; and
guiding immunosuppressant therapy to thereby optimize an ability to respond to infection and produce organ tolerance.

### Claim 2 (depends on 1)

The method of claim 1 wherein the TREC analysis comprises at least one of (a) determining levels of TREC using an assay and (b) analyzing TREC-correlated cell-markers.

### Claim 3 (depends on 2)

The method of claim 2 further comprising measuring TREC levels based upon at least one of the assays and the analyzing of the cell markers prior to transplant so as to provide a marker of immune competency in the organ transplant recipient.

### Claim 4 (depends on 2)

The method of claim 2 further comprising measuring TREC levels based upon at least one of the assay and the analyzing of the cell markers post-transplant so as to identify the organ transplant recipient's need and response to specific immunosuppressives.

### Claim 5 (depends on 2)

The method of claim 2 further comprising measuring the TREC levels based upon at least one of the assays and the analyzing of the cell markers so as to decrease a possibility of acute complications, such as post-transplant infections, and chronic complications, such as post-transplant cancers.

### Claim 6 (depends on 2)

A kit for the detection and quantification of T-cell receptor excision circles in organ transplant recipients for carrying out the method as set forth in claim 2.

### Claim 7 (depends on 3)

A kit for the detection and quantification of T-cell receptor excision circles in organ transplant recipients for carrying out the method as set forth in claim 3.

### Claim 8 (depends on 4)

A kit for the detection and quantification of T-cell receptor excision circles in organ transplant recipients for carrying out the method as set forth in claim 4.

### Claim 9 (depends on 5)

A kit for the detection and quantification of T-cell receptor excision circles in organ transplant recipients for carrying out the method as set forth in claim 5.

### Claim 10 (depends on 1)

The method of claim 1 wherein the cell marker correlates with thymic migrants.

### Claim 11 (depends on 10)

The method of claim 10 wherein the cell markers CD31 markers.

### Claim 12

A medical treatment method for determining and controlling of immune status in a transplant patient comprising the steps of:
separating cellular components that correlate with patient TREC levels;
analyzing the cellular components to determine the patient TREC levels; and
controlling immunosuppressant administration to the patient based upon the determined TREC levels.

### Claim 13 (depends on 12)

The medical treatment as set forth in claim 12 wherein the step of analyzing the cellular components includes analyzing TREC surrogates.

### Claim 14 (depends on 13)

The medical treatment method as set forth in claim 13 wherein the TREC surrogates include CD31 cell markers.

### Claim 15 (depends on 12)

A kit for performing the medical treatment method of claim 12 including compounds and instructional information.
